Nasal airflow in growth hormone treatment.
Nasal congestion due to hormonal influences has been recognized as a clinical entity, and a "hormonal rhinitis" has been proposed to occur in acromegaly. In this study we investigated the effect of low-dose recombinant human growth hormone over eight weeks on nasal congestion as measured by nasal peak flow in a randomized, placebo-controlled, double-blind crossover clinical trial in ten patients with short bowel syndrome. The treatment did not induce a significant nasal congestion. Whether higher doses as used in many catabolic conditions do remains to be determined.
Ellegård
E
E
Department of Otorhinolaryngology, Mölndal Hospital, Sweden.
Ellegård
L
L
D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000503:physiopathology*; D015508:Nasal Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010366:Peak Expiratory Flow Rate; D012778:Short Bowel Syndrome / Q000150:complications; D016896:Treatment Outcome
D013006:Growth Hormone